Bypassing Agents: Clinical Trials

2 trials of Bypassing Agents, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Recruiting 1

Follow Bypassing Agents: new trials by email Literature Review of Bypassing Agents trials Research Report on Bypassing Agents

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3
Phase 3RecruitingHoffmann-La Roche752025-06-272026-11-16
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
fitusiran, Bypassing agents - Hemophilia A, Hemophilia B
Phase 3CompletedGenzyme, a Sanofi Company602018-02-142022-03-28

Conditions studied

Blood Coagulation Disorders (1)  ·  Blood Coagulation Disorders, Inherited (1)  ·  Coagulation Protein Disorders (1)  ·  Genetic Diseases, Inborn (1)  ·  Genetic Diseases, X-Linked (1)  ·  Hematologic Diseases (1)  ·  Hemophilia A (1)  ·  Hemophilia B (1)  ·  Hemorrhagic Disorders (1)  ·  von Willebrand Disease, Type 3 (1)

Sponsors

Genzyme, a Sanofi Company (1)  ·  Hoffmann-La Roche (1)

Countries

Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  South Africa (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  Colombia (1)  ·  India (1)  ·  Malaysia (1)

Results publications

PMID 34922648, PMID 35114155, PMID 37003287

NIH funding

2016 (1)